Jump to ContentJump to Main Navigation
Show Summary Details

Open Medicine

formerly Central European Journal of Medicine

IMPACT FACTOR increased in 2015: 0.190
5-year IMPACT FACTOR: 0.221

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154
Impact per Publication (IPP) 2015: 0.197

Open Access
See all formats and pricing

Select Volume and Issue


Beneficial neurohumoral profile in left ventricular systolic dysfunction following acute myocardial infarction

1Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania

2Vilnius University Faculty of Mathematics, Vilnius, Lithuania

3Clinic of Cardiovascular disease, Vilnius University Medical Faculty, Vilnius, Lithuania

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Open Medicine. Volume 9, Issue 1, Pages 64–73, ISSN (Online) 2391-5463, DOI: 10.2478/s11536-012-0141-6, February 2014

Publication History

Published Online:


Keywords: Heart failure; Left ventricular systolic dysfunction; Renin-angiotensin-aldosterone system; NT-proBNP; Eplerenone

  • [1] Omland T., Aakvaag A., Bonarjee V.S., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963–1969 http://dx.doi.org/10.1161/01.CIR.93.11.1963 [CrossRef]

  • [2] Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47–54 http://dx.doi.org/10.1016/S1071-9164(96)80009-1 [CrossRef]

  • [3] Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–717 http://dx.doi.org/10.1056/NEJM199909023411001 [CrossRef]

  • [4] Rousseau M.F., Gurne O., Duprez D., Mieghem W., Robert A., Ahn S., Galanti.L, Ketelslegers J.M. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. J Am Coll Cardiol 2002; Vol 40

  • [5] Delyani, J.A., 2000. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 57, 1408–1411 http://dx.doi.org/10.1046/j.1523-1755.2000.00983.x [CrossRef]

  • [6] Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321. [Ephesus] http://dx.doi.org/10.1056/NEJMoa030207 [CrossRef]

  • [7] Zannad F., McMurray J.J.V., Drexler H., Krum H., Van Veldhusein J.D., Swedberg K., Shi H., Vincent J., Pitt B. Rationale and design of the Eplerenone in mild patients hospitalization and survival study in heart failure (Emphasis-HF). Eur J Heart Fail 2010; 12(6): 617–622 http://dx.doi.org/10.1093/eurjhf/hfq049 [CrossRef]

  • [8] ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. McMurray JJ., Adamopoulos S., Anker SD, Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., ESC Committee for Practice Guidelines. Eur J Heart Fail. 2012 Aug;14(8):803–869 http://dx.doi.org/10.1093/eurjhf/hfs105 [CrossRef]

  • [9] Forman D.E., Butler J., Wang Y., Abraham W.T., O’Connor C.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61–67 http://dx.doi.org/10.1016/j.jacc.2003.07.031 [CrossRef]

  • [10] Jose P., Skali H., Anavekar N., Tomson C., Krumholz H.M., Rouleau J.L., Moye L., Pfeffer M.A., Solomon S.D. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006;17:2886–2891 http://dx.doi.org/10.1681/ASN.2006010063 [CrossRef]

  • [11] Anavekar N.S., McMurray J.J., Velazquez E.J., Solomon S.D., Kober L., Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295 http://dx.doi.org/10.1056/NEJMoa041365 [CrossRef]

  • [12] Anand I.S., Bishu K., Rector T.S., Ishani A., Kuskowski M.A., Cohn J.N. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensinconverting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009; 120:1577–1584 http://dx.doi.org/10.1161/CIRCULATIONAHA.109.853648 [CrossRef]

  • [13] Francis G.S., Tang W.H. Pathophysiology of congestive heart failure. Rev Cardiovasc Med. 2003;4(Suppl 2):S14–S20

  • [14] Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–1697 http://dx.doi.org/10.1056/NEJMra000050 [CrossRef]

  • [15] Gradman A.H. Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention. Am Heart J 2009;157:S1–6 http://dx.doi.org/10.1016/j.ahj.2009.04.005 [Web of Science] [CrossRef]

  • [16] Rouleau J.L., Packer M., Moye L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583–591 http://dx.doi.org/10.1016/0735-1097(94)90001-9 [CrossRef]

  • [17] Hall C., Rouleau J.L., Moye L., et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934–42 http://dx.doi.org/10.1161/01.CIR.89.5.1934 [CrossRef]

  • [18] Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998;339:321–328 http://dx.doi.org/10.1056/NEJM199807303390507 [CrossRef]

  • [19] Tsutamato T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228–1233 http://dx.doi.org/10.1016/S0735-1097(01)01116-0 [CrossRef]

  • [20] Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61:663–670 http://dx.doi.org/10.1016/j.cardiores.2003.11.037 [CrossRef]

  • [21] Edelmann.F, Schmidt A.G., Gelbrich G., et al. Rationale and design of the “aldosterone receptor blockade in diastolic heart failure” trial: a doubleblind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010; 12:874–882. http://dx.doi.org/10.1093/eurjhf/hfq087 [CrossRef] [Web of Science]

  • [22] Weber K.T., Brilla C.G.. Pathological hypertrophy and cardiac interstitium: fibrosis and reninangiotensin-aldosterone system. Circulation 1991;83:1849–1865 http://dx.doi.org/10.1161/01.CIR.83.6.1849 [CrossRef]

  • [23] Silvestre J.S., Heymes C., Oubenaissa A., Robert V., Aupetit-Faisant B., Carayon A., Swynghedauw B., Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694–2701 http://dx.doi.org/10.1161/01.CIR.99.20.2694 [CrossRef]

  • [24] MacFadyen R.J., Lee A.F., Morton J.J., Pringle S.D., Struthers A.D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82:57–61 [CrossRef]

  • [25] Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J heart Fail 2004; 6: 539–545 http://dx.doi.org/10.1016/j.ejheart.2004.04.013 [CrossRef]

  • [26] Tang W.H., Vagelos R.H., Yee Y.G., et al. Neurohormonal and clinical responses to highversus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70–78 http://dx.doi.org/10.1016/S0735-1097(01)01714-4 [CrossRef]

  • [27] Vantrimpton P., Rouleau J.L., Ciampi A., Harel F., De Champlaint J., Bichet D., Moye JA. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular enlargement (SAVE) study. Eur Heart J 1998; 19: 1552–1563 http://dx.doi.org/10.1053/euhj.1998.1093 [CrossRef]

  • [28] Shirani J., Dilsizian V. Imaging left ventricular remodeling: targeting the neurohumoral axis. Nat Clin Pract Cardiovasc Med 2008;5 Suppl 2:S57–62 http://dx.doi.org/10.1038/ncpcardio1244 [CrossRef]

  • [29] Yancy C.W., Lee D.C. Personalized medicine in heart failure: are we there yet? J Am Coll Cardio Img 2012;5:419–421 http://dx.doi.org/10.1016/j.jcmg.2012.02.007 [CrossRef]

  • [30] Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17–22 http://dx.doi.org/10.1136/hrt.57.1.17 [CrossRef]

  • [31] Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., Hampton J.R., van Veldhuisen D.J. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210. http://dx.doi.org/10.1161/01.CIR.102.2.203 [CrossRef]

  • [32] Rossignol P., Cleland J.G., Bhandari S., Tala S., Gustafsson F., Fay R., Lamiral Z., Dobre D., Pitt B., Zannad F. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation. 2012 Jan 17;125(2):271–279. Epub 2011 Nov 29.

  • [33] Gupta S., Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J. 2005;26:644–6 http://dx.doi.org/10.1093/eurheartj/ehi176 [CrossRef]

  • [34] Ahmed A., Zannad F., Love T.E., et al. A propensity- matched study of the associationof low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007;28:1334–1343 http://dx.doi.org/10.1093/eurheartj/ehm091 [Web of Science] [CrossRef]

  • [35] Brown J.R., Uber P.A., Mehra M.R. The progressive cardiorenal syndrome in heart failure: mechanism and therapeutic insights. Curr Treat Options Cardiovasc Med 2008; 10: 342–348 http://dx.doi.org/10.1007/s11936-008-0054-5 [CrossRef]

  • [36] Weinfeld M.S., Chertow G.M., Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999; 138: 285–290 http://dx.doi.org/10.1016/S0002-8703(99)70113-4 [CrossRef]

Comments (0)

Please log in or register to comment.